Other clinical trials (NCT04275414, NCT04305106 and NCT04344782) have explored bevacizumab, a monoclonal antibody that binds and inhibits the major vascular permeability inducer, i.e., vascular endothelial growth factor (VEGF), that increases pulmonary edema during infection and that is also implicated in the induction of coagulation signaling pathways in severe COVID-19 [26]. Here, VEGFA is linked to infection.